Trial Profile
A randomised double-blind study in two parts Part A - Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC) and Part B - Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC) - BZ-01-002
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Fluorouracil; Folinic acid; Oxaliplatin; Pemetrexed
- Indications Colorectal cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Dr Reddys Laboratories
- 16 Jul 2018 Status changed from recruiting to completed.
- 26 Aug 2016 New trial record